Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions: aldesleukin, recombinant interferon alfa, sargramostim; Biological
Lead sponsor: Cancer Treatment Centers of America; Other
Eligibility: Not listed
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: Zion, Illinois

Conditions: Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions: BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis; Biological · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 174
States / cities: Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more

Conditions: Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions: Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor; Drug · Other · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 15 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Colorectal Cancer
Interventions: folic acid; Dietary Supplement
Lead sponsor: Eastern Cooperative Oncology Group; Network
Eligibility: 21 Years to 120 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 2009
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 1 more

Conditions: Mood Disorders, Bipolar Disorder, Major Depression
Interventions: Family-Focused Treatment with MCC App; Behavioral
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 13 Years to 19 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: High Risk Prostate Carcinoma, Biochemically Recurrent Prostate Carcinoma, Castration-resistant Prostate Cancer, Prostate Cancer
Interventions: Blood collection; Other
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 2
States / cities: Bala-Cynwyd, Pennsylvania • Pottstown, Pennsylvania

Conditions: Delirium, Ischemic Stroke, Acute Kidney Injury, Heart Valve Disease, Coronary Artery Disease
Interventions: CardioGard Embolic Protection Cannula, Standard Aortic Cannula; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 60 Years and older
Enrollment: 842 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 20
States / cities: North Little Rock, Arkansas • Los Angeles, California • Atlanta, Georgia + 16 more

Conditions: Older Men and Women With High Fall Risk
Interventions: Multi-Modality Balance Intervention, Balanced Reach Training (BRT); Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cardiac Surgery
Interventions: teprasiran, Placebo; Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,043 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 28 more

Conditions: Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult, Cervical Cancer, Colorectal Cancer, Esophageal Cancer, Esophageal Squamous Cell Carcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Merkel Cell Carcinoma, Microsatellite Instability-High Solid Malignant Tumor, Mismatch Repair Deficient Solid Malignant Tumor, Microsatellite Instability-High Colorectal Cancer, Mismatch Repair Deficient Colorectal Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma, Urothelial Carcinoma
Interventions: NEO212 Oral Capsule, Ipilimumab, Pembrolizumab, Nivolumab, Regorafenib, Carboplatin, Paclitaxel, FOLFIRI Protocol, Bevacizumab; Drug
Lead sponsor: Neonc Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Beverly Hills, California • Glendale, California • Los Angeles, California + 5 more

Conditions: Mammographic Breast Density
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 55 Years to 75 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Phenylketonuria
Interventions: saproterin dihydrochloride, Diet treatment; Drug · Other
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 2 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Conditions Requiring a Brain Magnetic Resonance Imaging, Head Computerized Tomography, or Head Ultrasound
Interventions: Hyperfine MRI; Diagnostic Test
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 0 Days to 22 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2030
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Glioma
Interventions: Temozolomide; Drug
Lead sponsor: Kentuckiana Cancer Institute; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Lymphoma
Interventions: Rituxan, BEAM, Autologous stem cell transplant; Drug · Procedure
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Cutaneous Squamous Cell Carcinoma
Interventions: Cemiplimab, Radiation Therapy; Drug · Radiation
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Risk
Interventions: RESPECT-IPV; Behavioral
Lead sponsor: The University of Akron; Other
Eligibility: Female only
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Glycogen Storage Disease Type II
Interventions: High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding; Other
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 17 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Body Image, Nutrition, Healthy
Interventions: Education; Other
Lead sponsor: Rocky Mountain Sports Medicine; Other
Eligibility: 14 Years to 18 Years · Female only
Enrollment: 49 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Parker, Colorado

Conditions: AML
Interventions: Azacitidine, APG1252; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Granulomatous Disease Transplant
Interventions: Alemtuzumab, Busulfan, Sirolimus, Cyclophosphamide, Total Body Irradiation, Peripheral blood stem cells; Drug · Radiation · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 4 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Abuse Cannabis, Pain, Pharmacokinetics
Interventions: Placebo Comparator: Placebo, Low dose THC, High dose THC; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 21 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: PONV
Interventions: APD421, Placebo; Drug
Lead sponsor: Acacia Pharma Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 14
States / cities: Sheffield, Alabama • San Francisco, California • Miami, Florida + 10 more

Conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
Interventions: Aldesleukin, Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL); Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer

S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

High-Dose Folic Acid in Preventing Colorectal Cancer in Patients Who Have Had Polyps Surgically Removed

Technology Enhanced Family Treatment

Characterization of Circulating Tumor Cells (CTCs) in High Risk and Early Metastatic Prostate Cancer Patients Using Parsortix® System

CTSN Embolic Protection Trial

A Balanced Assessment and Training Protocol (BATP) to Address Balance Disorders in Older and Neurologically Disabled Veterans

QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Effect of Aspirin on Mammogram Density in Healthy Postmenopausal Women With a Moderate or High Level of Breast Density

The Effectiveness of Kuvan in Amish PKU Patients

Low Field and High Field Magnetic Resonance Imaging Assessments on Pediatric Patients

A Phase II Study of Gliadel, Concomitant Temozolomide and Radiation, Followed By Dose Dense Therapy With Temozolomide For Newly Diagnosed Malignant High Grade Glioma

Rituxan and BEAM With Autologous Peripheral Blood Progenitor Transplant for Indolent Lymphoma

Cemiplimab and Quad Shot Radiation for Cutaneous Squamous Cell Carcinoma in the Head and Neck

Rapid HIV Testing and Counseling in High Risk Women in Shelters

High Protein and Exercise Therapy Plus Nocturnal Enteral Feeding in Juvenile-onset Pompe Disease

Improvement of Body Image Flexibility in High School Female Athletes Doing Educational About Nutrition and Body Image

Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML

High Dose Peripheral Blood Stem Cell Transplantation With Post Transplant Cyclophosphamide for Patients With Chronic Granulomatous Disease

High Potency Cannabis: Acute and Protracted Effects

Phase IIIb Study of APD421 in Combination as PONV Prophylaxis

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma